Company: BLRX
Filing Date: 2025-03-31
Form Type: 20-F
Source: 0001178913-25-001123
Chunk: 109

Company: BioLineRx Ltd.
Filing Date: 2025-03-31
Form: 20-F
Item: Item 3
Chunk 109
---
, we have a full right
of offset for amounts payable to the IIA for the motixafortide program from any payments that we may owe to Biokine in the future.

Environmental Matters

We are subject to various environmental, health and safety laws
and regulations, including those governing air emissions, water and wastewater discharges, noise emissions, the use, management and disposal
of hazardous, radioactive and biological materials and wastes and the cleanup of contaminated sites. We believe that our business, operations
and facilities are being operated in compliance, in all material respects, with applicable environmental and health and safety laws and
regulations. Based on information currently available to us, we do not expect environmental costs and contingencies to have a material
adverse effect on us. The operation of our facilities, however, entails risks in these areas. Significant expenditures could be required
in the future if we are required to comply with new or more stringent environmental or health and safety laws, regulations or requirements.
See “ Business - Government Regulation and Funding - Israel Ministry of Environment - Toxin Permit.”

C. Organizational Structure

Our corporate structure consists of BioLineRx Ltd., one wholly
owned subsidiary, BioLineRx USA, Inc., and a substantially wholly owned, inactive U. K. subsidiary, Agalimmune Ltd.

59

D. Property, Plant and Equipment

We are headquartered in Modi’in, Israel. We entered into
a lease agreement in August 2014, for an aggregate of 1,663 square meters (approximately 17,900 square feet) of space. Monthly rent is
NIS 128,300 (approximately $35,000), including maintenance fees and parking. The initial term of the lease expired in June 2020, and we
exercised our options to extend the lease through June 30, 2028. We have the option to extend the lease for one additional period of two
years, at a 5% increase to the preceding lease payment amount.

This facility houses both our administrative and research operations
and our central laboratory. The central laboratory consists of approximately 380 square meters (approximately 4,200 square feet) and includes
a bioanalytical laboratory, a formulation laboratory and a tissue culture laboratory. Our bioanalytical laboratory has received GLP certification.

In addition, in October 2022 we entered into a lease agreement
for our office in Waltham, Massachusetts for an aggregate of 4,880 square feet of space. Due to the shutdown of